PDS Biotechnology

Yahoo Finance • 22 days ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy si... Full story

Yahoo Finance • last month

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Au... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: PDS Biotech Q2 2025 reports narrower EPS loss, stock rises

PDS Biotechnology Corp (PDSB) reported a narrower-than-expected loss in its second quarter earnings for 2025, with an EPS of -$0.21, slightly beating the forecast of -$0.22. The company’s stock responded positively, showing a premarket inc... Full story

Yahoo Finance • 2 months ago

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB [https://www.chartmill.com/stock/quote/PDSB/profile]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$0.21, slightly better than the analyst consensus estimate of -... Full story

Yahoo Finance • 2 months ago

PDS Biotechnology GAAP EPS of -$0.21 beats by $0.02

* PDS Biotechnology press release [https://seekingalpha.com/pr/20199124-pds-biotech-reports-second-quarter-2025-financial-results-and-provides-clinical-programs] (NASDAQ:PDSB [https://seekingalpha.com/symbol/PDSB]): Q2 GAAP EPS of -$0.21... Full story

Yahoo Finance • 3 months ago

PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria

Investing.com - PDS Biotechnology Corp (NASDAQ:PDSB), currently valued at $59.4 million, has completed patient recruitment for Stage 1 of a clinical trial evaluating its PDS01ADC therapeutic in metastatic colorectal cancer (mCRC), meeting... Full story

Yahoo Finance • 4 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET... Full story

Yahoo Finance • 5 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab a... Full story

Yahoo Finance • 5 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,... Full story

Yahoo Finance • 6 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • 6 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • 6 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage... Full story

Yahoo Finance • 6 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotech... Full story

Yahoo Finance • 7 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • 7 months ago

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now availa... Full story

Yahoo Finance • 7 months ago

Life Sciences Investor Forum Agenda Announced for March 13th

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Ca... Full story

Yahoo Finance • 7 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • 7 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT was associated with greater and earlier... Full story

Yahoo Finance • 2 years ago

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and... Full story

Yahoo Finance • 2 years ago

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1Announced 2-year ove... Full story